Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3248814 | 0.91 | HRH4 (0.57) | RAB9AHRH4KMT2AMEN1POLB | |
| SCHEMBL14845693 | 0.75 | NPC1 (0.97) | NPC1RAB9AHRH4KMT2AMEN1 | |
| SCHEMBL3855959 | 0.75 | HRH4 (0.59) | HRH4POLBDRD3DRD2 | |
| SCHEMBL2399212 | 0.74 | NPC1 (0.55) | NPC1RAB9AHRH4KMT2AMEN1 | |
| SCHEMBL3841732 | 0.74 | IP6K1 (0.60) | KMT2APOLB | |
| SCHEMBL12334169 | 0.74 | NPC1 (1.00) | NPC1RAB9AHRH4KMT2AMEN1 | |
| SCHEMBL17938665 | 0.73 | NPC1 (0.78) | NPC1RAB9AHRH4KMT2AMEN1 | |
| SCHEMBL601515 | 0.73 | HRH4 (1.00) | NPC1RAB9AHRH4KMT2AMEN1 | |
| SCHEMBL3252765 | 0.72 | HRH4 (0.58) | NPC1HRH4KMT2AMEN1AKR1C3 | |
| SCHEMBL14845692 | 0.72 | NPC1 (0.76) | NPC1RAB9AHRH4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202993-B2 | 5-bromo-1'-[(6-bromo-1H-indol-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | NPC1 2144/4885RAB9A 399/4885HRH4 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.